Literature DB >> 25999042

Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.

Roberto Frau1, Federico Abbiati2, Valentina Bini3, Alberto Casti4, Donatella Caruso2, Paola Devoto1, Marco Bortolato5.   

Abstract

BACKGROUND: Cogent evidence has shown that schizophrenia vulnerability is enhanced by psychosocial stress in adolescence, yet the underpinnings of this phenomenon remain elusive. One of the animal models that best capture the relationship between juvenile stress and schizophrenia is isolation rearing (IR). This manipulation, which consists in subjecting rats to social isolation from weaning through adulthood, results in neurobehavioral alterations akin to those observed in schizophrenia patients. In particular, IR-subjected rats display a marked reduction of the prepulse inhibition (PPI) of the startle reflex, which are posited to reflect imbalances in dopamine neurotransmission in the nucleus accumbens (NAcc). We recently documented that the key neurosteroidogenic enzyme 5α-reductase (5αR) plays an important role in the dopaminergic regulation of PPI; given that IR leads to a marked down-regulation of this enzyme in the NAcc, the present study was designed to further elucidate the functional role of 5αR in the regulation of PPI of IR-subjected rats.
METHODS: We studied the impact of the prototypical 5αR inhibitor finasteride (FIN) on the PPI deficits and NAcc steroid profile of IR-subjected male rats, in comparison with socially reared (SR) controls.
RESULTS: FIN (25-100 mg/kg, i.p.) dose-dependently countered IR-induced PPI reduction, without affecting gating integrity in SR rats. The NAcc and striatum of IR-subjected rats displayed several changes in neuroactive steroid profile, including a reduction in pregnenolone in both SR and IR-subjected groups, as well as a decrease in allopregnanolone content in the latter group; both effects were significantly opposed by FIN.
CONCLUSIONS: These results show that 5αR inhibition counters the PPI deficits induced by IR, possibly through limbic changes in pregnenolone and/or allopregnanolone concentrations.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5α-Reductase; Isolation rearing; Neurosteroids; Prepulse inhibition; Schizophrenia; Sensorimotor gating

Mesh:

Substances:

Year:  2015        PMID: 25999042      PMCID: PMC4628592          DOI: 10.1016/j.schres.2015.04.044

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  72 in total

Review 1.  Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence.

Authors:  C E Marx; D W Bradford; R M Hamer; J C Naylor; T B Allen; J A Lieberman; J L Strauss; J D Kilts
Journal:  Neuroscience       Date:  2011-07-01       Impact factor: 3.590

2.  Improvement of general symptoms in a chronic psychotic patient treated with finasteride: case report.

Authors:  D Koethe; M Bortolato; D Piomelli; F M Leweke
Journal:  Pharmacopsychiatry       Date:  2008-05       Impact factor: 5.788

3.  Isoniazid-induced inhibition of GABAergic transmission enhances neurosteroid content in the rat brain.

Authors:  M L Barbaccia; G Roscetti; M Trabucchi; R H Purdy; M C Mostallino; C Perra; A Concas; G Biggio
Journal:  Neuropharmacology       Date:  1996       Impact factor: 5.250

4.  Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation.

Authors:  E Dong; K Matsumoto; V Uzunova; I Sugaya; H Takahata; H Nomura; H Watanabe; E Costa; A Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

5.  Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.

Authors:  Rael D Strous; Rachel Maayan; Raya Lapidus; Rafael Stryjer; Michal Lustig; Moshe Kotler; Abraham Weizman
Journal:  Arch Gen Psychiatry       Date:  2003-02

6.  Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology.

Authors:  Rael D Strous; Rachel Maayan; Raya Lapidus; Leonid Goredetsky; Ella Zeldich; Moshe Kotler; Abraham Weizman
Journal:  Schizophr Res       Date:  2004-12-01       Impact factor: 4.939

Review 7.  Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders.

Authors:  Kevin C F Fone; M Veronica Porkess
Journal:  Neurosci Biobehav Rev       Date:  2008-03-18       Impact factor: 8.989

Review 8.  Modulation of brain dopamine transmission by sex steroids.

Authors:  T Di Paolo
Journal:  Rev Neurosci       Date:  1994 Jan-Mar       Impact factor: 4.353

9.  Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.

Authors:  K H Nuechterlein; M E Dawson; M Gitlin; J Ventura; M J Goldstein; K S Snyder; C M Yee; J Mintz
Journal:  Schizophr Bull       Date:  1992       Impact factor: 9.306

Review 10.  Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission.

Authors:  Sean C Godar; Marco Bortolato
Journal:  Front Behav Neurosci       Date:  2014-03-06       Impact factor: 3.558

View more
  11 in total

1.  The 5α-Reductase Inhibitor Finasteride Exerts Neuroprotection Against Ischemic Brain Injury in Aged Male Rats.

Authors:  Motoki Tanaka; Takunori Ogaeri; Mikhail Samsonov; Masahiro Sokabe
Journal:  Transl Stroke Res       Date:  2018-03-25       Impact factor: 6.829

2.  The Neurosteroidogenic Enzyme 5α-Reductase Mediates Psychotic-Like Complications of Sleep Deprivation.

Authors:  Roberto Frau; Valentina Bini; Alessio Soggiu; Simona Scheggi; Alessandra Pardu; Silvia Fanni; Paola Roncada; Monica Puligheddu; Francesco Marrosu; Donatella Caruso; Paola Devoto; Marco Bortolato
Journal:  Neuropsychopharmacology       Date:  2017-02-15       Impact factor: 7.853

3.  The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting.

Authors:  Gabriele Floris; Simona Scheggi; Romina Pes; Marco Bortolato
Journal:  Brain Res Bull       Date:  2022-02-03       Impact factor: 3.715

4.  Finasteride inhibited brain dopaminergic system and open-field behaviors in adolescent male rats.

Authors:  Li Li; Yun-Xiao Kang; Xiao-Ming Ji; Ying-Kun Li; Shuang-Cheng Li; Xiang-Jian Zhang; Hui-Xian Cui; Ge-Ming Shi
Journal:  CNS Neurosci Ther       Date:  2017-12-06       Impact factor: 5.243

5.  Steroid 5α-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors.

Authors:  Laura J Mosher; Sean C Godar; Marc Morissette; Kenneth M McFarlin; Simona Scheggi; Carla Gambarana; Stephen C Fowler; Thérèse Di Paolo; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2018-02-16       Impact factor: 4.905

6.  The neurosteroidogenic enzyme 5α-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating.

Authors:  Roberto Frau; Laura J Mosher; Valentina Bini; Giuliano Pillolla; Romina Pes; Pierluigi Saba; Silvia Fanni; Paola Devoto; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2015-09-24       Impact factor: 4.905

Review 7.  Neurobehavioural complications of sleep deprivation: Shedding light on the emerging role of neuroactive steroids.

Authors:  Roberto Frau; Francesco Traccis; Marco Bortolato
Journal:  J Neuroendocrinol       Date:  2019-09-30       Impact factor: 3.627

Review 8.  Androgen Regulation of the Mesocorticolimbic System and Executive Function.

Authors:  Daniel J Tobiansky; Kathryn G Wallin-Miller; Stan B Floresco; Ruth I Wood; Kiran K Soma
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-05       Impact factor: 5.555

Review 9.  Neurosteroids in Schizophrenia: Pathogenic and Therapeutic Implications.

Authors:  HuaLin Cai; Ting Cao; Xiang Zhou; Jeffrey K Yao
Journal:  Front Psychiatry       Date:  2018-03-08       Impact factor: 4.157

10.  The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia.

Authors:  Marta De Felice; Miriam Melis; Sonia Aroni; Anna Lisa Muntoni; Silvia Fanni; Roberto Frau; Paola Devoto; Marco Pistis
Journal:  CNS Neurosci Ther       Date:  2018-11-21       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.